Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCORE: Quetiapine + CRT in Schizophrenia
NCT00255515Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2005
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of quetiapine (extended-release tablet, brand name: Bipresso) in schizophrenia (3 arms), sponsored by AstraZeneca. Primary endpoint: Social outcome measured by Strauss-Carpenter scale. Started Sep 2005; status: completed.
02
Drugs
quetiapine (extended-release tablet, brand name: Bipresso)
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00255515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00255515.